Sign in

You're signed outSign in or to get full access.

Ben Hendricks

Vice President and Senior Equity Analyst at RBC Capital Markets

Ben Hendrix is a Vice President and Senior Equity Analyst at RBC Capital Markets, specializing in the healthcare and financial services sectors with a focus on companies such as UnitedHealth Group, Walgreens Boots Alliance, LHC Group, and Amedisys. He covers over 30 stocks and has maintained a success rate of approximately 54% with an average return of 3% per rating, and his most profitable stock call generated a return of over 270%. Ben began his career as an Associate Product Manager at INVESCO, then held associate roles in investment banking at UBS and Wells Fargo Securities before joining RBC Capital Markets in 2013, where he advanced from Assistant Vice President to his current role. He holds an MBA in Finance and Accounting from Vanderbilt University and a BSM from Tulane University, and is FINRA-registered, reflecting his professional credentials in the securities industry.

Ben Hendricks's questions to Elevance Health (ELV) leadership

Question · Q4 2025

Ben Hendrix asked for clarification on the Carelon margin discussion, specifically regarding the expansion of risk-based solutions in Carelon Services through 2025, new services or product lines where risk is being taken, and the degree to which this expansion could offset shifting margin dynamics in CarelonRx.

Answer

Pete Haytaian, President of Carelon, explained that Carelon takes a very intentional and disciplined approach to risk, with a diverse mix of fee-based and risk business, including category-of-service and whole-health risk, with appropriate protections. He noted that risk is assumed in most product offerings, and new offerings like SMI, oncology, and CareBridge are risk offerings that deliver value. Gail Boudreaux, President and CEO, added that a strong external growth pipeline validates this approach, focusing on serving complex populations based on internal health plan experience. Gail Boudreaux, President and CEO, added a brief closing remark.

Ask follow-up questions

Fintool

Fintool can predict Elevance Health logo ELV's earnings beat/miss a week before the call

Question · Q4 2025

Ben Hendrix asked about the new services under Carelon Services where Elevance is taking risk, and the extent to which this expansion could offset the shifting margin dynamics mentioned in CarelonRx.

Answer

Pete Haytaian, President of Carelon, Elevance Health, explained that Carelon takes on risk intentionally and disciplinedly, with a diverse set of services and a mix of fee-based and risk business (category of service or whole health risk). He noted that new offerings like Severe Mental Illness (SMI), oncology, and CareBridge are risk offerings that deploy value from a cost of care and quality perspective for the enterprise.

Ask follow-up questions

Fintool

Fintool can write a report on Elevance Health logo ELV's next earnings in your company's style and formatting

Ben Hendricks's questions to HCA Healthcare (HCA) leadership

Question · Q4 2025

Ben Hendrix asked for HCA Healthcare's initial thoughts on the potential transition to a health savings account (HSA) construct for enhanced subsidies, its impact on EPTC expiry headwinds, and uncompensated care, assuming funds go directly to customer HSAs.

Answer

CFO Mike Marks acknowledged President Trump's healthcare plan announcement, which included themes like improving affordability and potentially changing to cash in HSAs instead of exchange tax credits. However, he stated it's too early to size potential impacts as the plan's aspects and congressional reactions are still uncertain, and HCA is monitoring developments closely.

Ask follow-up questions

Fintool

Fintool can predict HCA Healthcare logo HCA's earnings beat/miss a week before the call

Question · Q4 2025

Ben Hendrix asked for HCA's thoughts on the potential transition to a Health Savings Account (HSA) construct for enhanced subsidies, assuming funds go directly to customer HSAs. He questioned how this would impact the current assessment of EPTC expiry headwinds and uncompensated care, especially if patients have access to funds but do not purchase insurance.

Answer

CFO Mike Marks stated it's too early to size the potential impacts from President Trump's recent healthcare plan announcement, which included themes of improving affordability, insurance plan accounts, pharmaceutical prices, price transparency, and potentially shifting to cash in HSAs. He noted that HCA is monitoring developments closely as they flow through Congress and will provide updates when more information is available.

Ask follow-up questions

Fintool

Fintool can write a report on HCA Healthcare logo HCA's next earnings in your company's style and formatting

Ben Hendricks's questions to PACS Group (PACS) leadership

Question · Q3 2025

Ben Hendricks asked how local market referral and payer relationships fared during the audit process, and if any changes were made with key sources. He also inquired if operational changes from the audit have altered M&A target selection, specifically balancing deep turnaround opportunities versus already well-performing facilities.

Answer

Jason Murray (CEO) explained that the locally led, centrally supported model allowed administrators to adapt to local market needs, and strong census numbers indicated PACS remained the provider of choice, demonstrating the model's resilience. He confirmed that relationships remained strong. Jason Murray stated that the company's disciplined M&A evaluation process, involving an investment committee, has not changed. He affirmed that PACS will continue to pursue deep turnaround opportunities, like the Colorado example, where their model can transform struggling facilities clinically and financially, deploying resources to improve quality metrics in a disciplined manner.

Ask follow-up questions

Fintool

Fintool can predict PACS Group logo PACS's earnings beat/miss a week before the call

Question · Q3 2025

Ben Hendricks asked about the local market strategy, specifically how referral and payer relationships fared during the audit process and if any changes were necessary. He also inquired if the operational changes resulting from the audit have altered the company's M&A target selection, particularly the balance between deep turnaround opportunities and already well-performing facilities.

Answer

Jason Murray, CEO, emphasized that the locally led, centrally supported model allowed administrators to adapt to local market needs, which proved resilient during challenging times. He pointed to strong census numbers as evidence that PACS remains the provider of choice, confirming that relationships in their markets held up well. Regarding M&A targets, Mr. Murray stated that there has been no change in thinking. The company continues to use its disciplined investment committee structure to evaluate deals and will continue to pursue deep turnaround opportunities, as they are confident in their ability to transform struggling facilities clinically and financially.

Ask follow-up questions

Fintool

Fintool can write a report on PACS Group logo PACS's next earnings in your company's style and formatting